My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Substances
Nebivolol

Nebivolol

A-Z
Search for:
NEBIMED 5
Deus Medical
Substance Overview and History

Introduced by Van de Water et al. in 1988 as a third generation beta blocker Nebivolol has become well known for its impact, on β1 receptors and distinct vasodilatory characteristics It received FDA approval in 2007 for treating hypertension. Nebivolol is distinguished by its side effect profile which makes it ideal for patients, with mild obstructive pulmonary disease and a low likelihood of erectile dysfunction. Studies discovered its benefits, against uveal melanoma tumors and demonstrated how it plays a double role in maintaining heart health while opening up new paths, in cancer treatment.

References:

Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is Nebivolol?
Nebivolol is a third generation beta-blocker primarily used to treat hypertension.
References:

Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.

When was Nebivolol developed?
Nebivolol was introduced by Van de Water et al. in 1988 and received FDA approval in 2007.
References:

Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.

What makes Nebivolol drug different from other beta-blockers?
Is highly selective for β1 receptors and has additional vasodilatory properties, which contribute to a favorable side effect profile.
References:

Farhoumand, L.S., Liu, H., Tsimpaki, T., Hendgen-Cotta, U.B., Rassaf, T., Bechrakis, N.E., Fiorentzis, M. and Berchner-Pfannschmidt, U., 2023. Blockade of ß-Adrenergic Receptors by Nebivolol Enables Tumor Control Potential for Uveal Melanoma in 3D Tumor Spheroids and 2D Cultures. International Journal of Molecular Sciences.